Despite years of use of gold-standard therapy levodopa, therapeutic development in Parkinson disease has advanced rapidly and expanded to numerous novel pathways and targets.
Luke Lovelace
Advertisement
Associate director of Clinical Trials, Department of Neurology, Georgetown University, in Washington, DC
Articles by Luke Lovelace
Advertisement
Latest Updated Articles
Promising Disease-Modifying Therapies in Parkinson DiseasePublished: April 19th 2023 | Updated:
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial
2
NeurologyLive® Brain Games: October 19, 2025
3
RWJBarnabas and Rutgers Health Researchers Pursue Advanced Neurostimulation Technology to Treat Epileptic Seizures
4
Refining Neonatal Continuous EEG Guidelines Through Evidence and Family Collaboration: Adam Numis, MD
5
